Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04822181 · ClinicalTrials.gov registry record · Phase 3
Research Study on Whether Semaglutide Works in People With Non-alcoholic Steatohepatitis (NASH)
A Phase 3 study of Nonalcoholic Steatohepatitis, sponsored by Novo Nordisk A/S.
- Active
- Registry status
- Phase 3
- Development phase
- 1,205
- Enrollment target
- 20
- Study locations
NCT04822181: Active Phase 3 study of Nonalcoholic Steatohepatitis, sponsored by Novo Nordisk A/S.
NCT04822181 is a Phase 3 study of Nonalcoholic Steatohepatitis that is active but no longer recruiting, run by Novo Nordisk A/S. The registered enrollment target is 1,205 participants, above the 662-participant average among 30 other Nonalcoholic Steatohepatitis trials with a reported enrollment target (82% higher). The trial reports 20 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04822181, a Phase 3 study of Nonalcoholic Steatohepatitis, is active but no longer recruiting, sponsored by Novo Nordisk A/S.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 1,205 participants
- Enrollment target
- 20
- Study locations
Study Summary
Semaglutide is a medicine studied in patients with NASH. Semaglutide is a well-known medicine, which is already used by doctors to treat type 2 diabetes in many countries. Participants will either get semaglutide or a dummy medicine - which treatment participants get is decided by chance. Participants will need to inject themselves with medicine under the skin. Participants will need to do this once a week. The study will last for about 5 years. Participants will have up to 21 clinic visits and 9 phone calls with the clinical staff during the study. Some of the clinic visits may be spread over more than one day. Participants with other chronic liver diseases cannot take part in this study. Women cannot take part in the study if they are pregnant, breast-feeding or plan to become pregnant during the study period.
Primary Outcome
Count of subject
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Semaglutide
Study Locations (20)
California
- Gastroenterology & Liver Institute - Escondido
- Shang Wu M.D. Inc. - Hacienda Heights
- Scripps Whittier Diabetes Inst - La Jolla
- UCSD NAFLD Research Center - La Jolla
- OM Research LLC - Lancaster
- Digestive Hlth Res of SoCa - Long Beach
- OM Research LLC - Oxnard
- Cedars-Sinai Medical Center - Pasadena
- Pasedena Liver Center - Pasadena
- Inland Empire Clin Trials LLC - Rialto
- UC Davis Hlth -Midtwn Ambu Cen - Sacramento
- University of California, San Francisco - San Francisco
Arizona
- The Institute for Liver Health - Chandler
- Inst-Liver Hlth dba AZ Liver H - Peoria
- Inst. Liver H II dba AZ Liver H - Tucson
- Del Sol Research Management, LLC - Tucson
Arkansas
- ARcare Center for Clinical Research - Jonesboro
- ARcare Center for Clinical Research - Little Rock
- Arkansas Diagnostic Center, PA - Little Rock
Alabama
- North AL Health Res, LLC - Huntsville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,205 participants |
| Start Date | 2021-04-01 |
| Est. Completion | 2029-04-25 |
| Phase | Phase 3 |
What the registry record for NCT04822181 still lists
NCT04822181 is an interventional study that assigns participants to a tested intervention. Its 1,205 participants enrollment target places it among the larger protocols in the corpus, above the 662-participant average among 30 other Nonalcoholic Steatohepatitis trials with a reported enrollment target (82% higher).
The record links to 1 condition, with Nonalcoholic Steatohepatitis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT04822181 names 20 study sites across 4 states, led by California, Arizona, Arkansas.
Frequently Asked Questions
What is clinical trial NCT04822181 about?
NCT04822181 is a clinical study titled "Research Study on Whether Semaglutide Works in People With Non-alcoholic Steatohepatitis (NASH)". Semaglutide is a medicine studied in patients with NASH. Semaglutide is a well-known medicine, which is already used by doctors to treat type 2 diabetes in many countries. Participants will either get semaglutide or a dummy medicine - which treatment participants get is decided by chance. Particip...
What is the current status of trial NCT04822181?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 1,205 participants. The study started on 2021-04-01. Estimated completion is 2029-04-25.
What conditions does trial NCT04822181 study?
This clinical trial studies the following conditions: Nonalcoholic Steatohepatitis.
What interventions are being tested in trial NCT04822181?
The interventions under investigation include: Placebo (DRUG), Semaglutide (DRUG).
Who is sponsoring clinical trial NCT04822181?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04822181 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Nonalcoholic Steatohepatitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04822181's enrollment target sits among peer trials
1,205 2nd of 30 the highest of 30 other Nonalcoholic Steatohepatitis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Nonalcoholic Steatohepatitis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Longitudinal Multi-Omic Profiles to Reveal Mechanisms of Obesity-Mediated Insulin Resistance
RECRUITING · NA
-
Low-Dose Pioglitazone in Patients With NASH (AIM 2)
RECRUITING · Phase 2
-
A Longitudinal Observational Study of Patients With Nonalcoholic Steatohepatitis (NASH) and Related Conditions Across the Entire Spectrum of Nonalcoholic Fatty Liver Disease (NAFLD)
RECRUITING
-
Thyroid Hormone for Treatment of Nonalcoholic Steatohepatitis in Veterans
RECRUITING · Phase 2
-
Metabolic Pathology of Pediatric NAFLD
RECRUITING · NA
-
Predicting Outcomes in Nonalcoholic Steatohepatitis With Advanced Fibrosis
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06535854 · 1,205 participants · NA
Prevail Global Study
- NCT07223593 · 1,205 participants · Phase 3
Efficacy and Safety of Orforglipron in Participants With Peripheral Artery Disease
- NCT07038785 · 1,204 participants
Identification of Breast Cancer in Breath Samples Using Trained Detection Dogs
- NCT05946213 · 1,209 participants · Phase 3
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI